Trials
2 active
5 in total · 1 in the EU
What this is
- How it works
- A short strand of genetic material that blocks one gene's message, so the body makes less of one protein.Antisense Oligonucleotide FDA class
- Tested for
- Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
- Main trialPhase 4
- “In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in people who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1. This is known as a "postmarketing" study. In this kind of the study, the goal is to learn more about how a drug works after it has been approved for use in the general public. Tofersen was approved in China in September 2024. The main goal of this study is to collect…”In the company’s words, NCT07223723 on ClinicalTrials.gov
- Other names
- BIIB067 · QALSODY
Other drugs for Amyotrophic Lateral Sclerosis
Coming up2
- 26 May 2027Phase 4 trial completes · ClinicalTrials.gov
- 7 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 26 May 2027 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 3Active, not recruiting | 7 Aug 2027 | Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | |
| Phase 3Completed | 16 Jul 2021 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 3Completed | 12 Aug 2024 | Long-Term Evaluation of BIIB067 (Tofersen) | |
| Phase 1Completed | 10 Jun 2021 | A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026